|Articles|July 1, 2004
Phase III study eyes intravitreal therapy for exudative AMD
Anti-VEGF monoclonal antibody fragment improves vision, reduce fluorescein angiographic leakage
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
PRIMAvera study: Central vision improvement with subretinal implant
2
Refractory dry eye care: How systemic conditions change the game
3
The year in optometry: 10 stories that defined eye care in 2025
4
Molecular insights and clinical experience: Extending anti-VEGF durability
5